Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Russia drone attacks
Former assistant found slain
Renegotiates prenup
Miss USA 2023
UKR shoots down 30 drones
Beaver born after 400 years
Migrants risk rape
6,000-year-old sandals found
To ban caste discrimination
X losing daily active users
Making NHL history
Nabs $2M in preview
Wins an Emmy
6 killed in mine collapse
Signs 1-yr contract extension
Files for bankruptcy
Primo suspended 4 games
Giants fire Gabe Kapler
Pope creates 21 cardinals
Plans to attend civil trial
PK bombing: Death toll rises
3 BRPD officers arrested
US operations chief resigns
Staples' ex-exec sentenced
Sea lion escapes zoo
Canceled at ABC
Homeless sue Portland
To make NFL return
Red wolf needs help to live
To run as independent?
Faces new civil suit
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
162,000 results
1d
First FDA Approved Drug to Slow Alzheimer’s
Joan was diagnosed with early-stage Alzheimer’s disease. There was nothing doctors could do. But now, a recently FDA-approved ...
朝日新聞社11d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
1d
FDA advisers vote against experimental ALS treatment pushed by patients
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...
9don MSN
Medical Moment: FDA approves first-ever drug to slow Alzheimer’s
There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
Washington Examiner29d
FDA needs to let go of its risk-averse regulatory model
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
pharmaphorum5d
FDA issues draft guidance for Alzheimer’s drug development
The US FDA has issued proposal guidance to assist companies developing new treatments for patients in the early stages of Alzheimer’s disease, before the onset of noticeable (overt) dementia.
Forbes19d
What To Know About The Alzheimer’s Drug Leqembi
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
4d
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.
21hon MSN
FDA wants to regulate thousands of lab tests that have long skirted oversight
The Food and Drug Administration says it plans to begin regulating laboratory-based medical tests. It's a multibillion-dollar industry that regulators say poses a growing risk to patients.
The Financial Times26d
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
朝日新聞社2d
Alzheimer’s drug lecanemab set to soon be approved for use in Japan
A medication that could help treat early stages of Alzheimer's disease is on track to be approved for manufacturing and sales in Japan after being endorsed by a health ministry expert panel on ...
WISH-TV
2d
Health Spotlight: First FDA-approved drug to slow Alzheimer’s
More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices